+86-28-82633987sales@biopurify.com
cnen
  • iso9001 iso9001
  • iso17025 iso17025
  • usp usp
Alternate Text
Home > Literature List > Sequentially releasing dual-drug-loaded PLGA–casein core/shell nanomedicine: Design, synthesis, biocompatibility and pharmacokinetics

Sequentially releasing dual-drug-loaded PLGA–casein core/shell nanomedicine: Design, synthesis, biocompatibility and pharmacokinetics

Journal name:Acta Biomaterialia
Literature No.:
Literature Url: http://www.sciencedirect.com/science/article/pii/S1742706113006466
Date publication:May 2014


Sequentially releasing dual-drug-loaded PLGA–casein core/shell nanomedicine: Design, synthesis, biocompatibility and pharmacokinetics

Sreeja Narayanan, Maya Pavithran,Aiswarya Viswanath, Dhanya Narayanan, Chandini C. Mohan, K. Manzoor, Deepthy Menon, 

Abstract

The present study reports an engineered poly-l-lactide-co-glycolic acid (PLGA)–casein polymer–protein hybrid nanocarrier 190 ± 12 nm in size entrapping a combination of chemically distinct (hydrophobic/hydrophilic) model drugs. A simple emulsion–precipitation route was adopted to prepare nearly monodispersed nanoparticles with distinct core/shell morphology entrapping paclitaxel (Ptx) in the core and epigallocatechin gallate (EGCG) in the shell, with the intention of providing a sequential and sustained release of these drugs. The idea was that an early release of EGCG would substantially increase the sensitivity of Ptx to cancer, thereby providing improved

 EGCG from Chengdu Biopurify Phytochemicals Ltd., PR China. 

Related Products